Diana M. Watral, P.C.
Overview
Diana is a rockstar and a brilliant lawyer. Her level of client service is outstanding. - Chambers USA
Diana Watral is a Chambers-ranked litigation partner and trial lawyer who represents companies in complex commercial and bet-the-company litigation. She focuses on high-stakes matters for some of the world’s largest pharmaceutical and life sciences companies, with an emphasis on multidistrict litigation, products liability, False Claims Act, contract disputes and class actions.
Diana currently leads three major multidistrict litigations for Eli Lilly and Company related to insulin pricing and GLP-1 products liability claims, as well as Lilly’s nationwide litigation against sellers of knock-off GLP-1 weight loss medicines. She recently led Lilly’s successful defense against a preliminary injunction brought by its biggest competitor, Novo Nordisk, concerning GLP-1 medicines—a win that earned Diana Litigator of the Week. She also represents Lilly in numerous other significant matters in state and federal courts throughout the country.
Diana is an experienced trial lawyer. She led Lilly’s defense in a $1.25 billion breach-of-contract jury trial; served as lead trial counsel to Flexus Biosciences, a Bristol-Myers Squibb subsidiary, in a $1 billion trade secret jury trial; defended Abbott in a $1 billion False Claims Act jury trial; and defended Baxter Healthcare in a $400 million contract trial and multiple products liability trials. She also led the defense of a large pharmaceutical company in an arbitration in which a competitor sought to invalidate a patent-royalty agreement and led the defense of a breach-of-contract arbitration for a large oil company.
Diana led Allergan (AbbVie) to defeat a massive False Claims Act case at summary judgment, where the relator alleged a nationwide, 15-year scheme to defraud the government through kickbacks and off-label promotion. She also obtained dismissal of an antitrust case asserting that AbbVie created a “patent thicket” for Humira, the highest-selling drug in history and dismissal of False Claims Act retaliation claims brought against AbbVie by several former employees following an Office of Ethics and Compliance investigation.
Chambers USA has described Diana as “whip smart,” “a rockstar” and “a brilliant lawyer.” Legal 500 United States has recognized her for Healthcare: Life Sciences, calling her “brilliant, creative and tenacious,” and named her a “Next Generation Partner” in Commercial Disputes. Crain’s recognized Diana as a “Notable Litigator and Trial Attorney,” and she was named one of four Law360 “Rising Stars” for her trial work. She was also profiled by Bloomberg Law in its “They’ve Got Next” series for Healthcare and Life Sciences and is named on the Benchmark Litigation “40 & Under Hot List” for her products liability, commercial litigation and False Claims Act work. Diana has been profiled twice as Litigator of the Week for her work for Lilly and Bristol-Myers Squibb.
Experience
Representative Matters
Pharmaceutical, Products Liability and Life Sciences
- GLP-1 Gastroparesis Products Liability MDL: Lead counsel for Lilly in products liability MDL alleging GLP-1 medicines cause gastroparesis and other serious gastrointestinal adverse events.
- GLP-1 NAION Products Liability MDL: Lead counsel for Lilly in products liability MDL alleging GLP-1 medicines cause NAION, a rare eye injury.
- Insulin Pricing MDL: Lead counsel for Lilly in multidistrict litigation involving a consumer class action, dozens of attorney general cases and hundreds of county, union and school district cases. Obtained denial of class certification for consumer class, dismissal of insurer lawsuit with prejudice after full discovery and non-monetary settlements with several state attorneys general.
- Nektar v. Lilly: Lead trial counsel for Lilly in two-week $1.25 billion breach-of-contract jury trial relating to development of immunology drug. After five days of deliberation, jury ruled for Lilly on main breach-of-contract claim and awarded only 7% of requested damages on secondary claim.
- GLP-1 Compounding Matters: Lead counsel for Lilly in nationwide litigation against sellers and manufacturers of knock-off versions of Lilly’s weight loss medicine, Zepbound. Obtained multiple favorable settlements requiring defendants to stop selling illegal products.
- Zyprexa Products Liability Litigation: Represent Lilly in multi-state products liability litigation alleging Zyprexa causes breast cancer.
- Novo Nordisk v. Lilly: Lead counsel for Lilly in false advertising case concerning ads for Lilly’s GLP-1 medicines, Mounjaro and Zepbound. Successfully defeated preliminary injunction. Recognized as Litigator of the Week for her win.
- Humira Antitrust Litigation: Counsel for AbbVie in multidefendant antitrust case regarding Humira, the highest-selling drug in history, where plaintiffs assert that AbbVie amassed a “patent thicket” of over 100 patents and entered anticompetitive settlement agreements with biosimilar manufacturers. District court dismissed entire complaint with prejudice, and Seventh Circuit affirmed dismissal.
- Incyte v. Flexus Biosciences: Led successful $1 billion trial for Flexus, now a Bristol-Myers Squibb subsidiary, in dispute alleging misappropriation of trade secrets for cancer drugs. At summary judgment, successfully eliminated six of eight alleged trade secrets and cut damages by half. Trial resulted in a unanimous jury verdict for all defendants. The American Lawyer recognized Diana as its national “Litigator of the Week” for her trial success, and Benchmark Litigation recognized the case as its 2019 “National Impact Case of the Year.”
- Confidential Arbitration: Led arbitration for large pharmaceutical company against attempt to invalidate patent-royalty agreement. Arbitrators unanimously ruled for Diana’s client.
- Heparin Products Liability Litigation: Trial counsel for Baxter in multidistrict litigation involving allegedly contaminated heparin. State court trial resulted in full defense verdict. MDL court granted Daubert and summary judgment motions on several categories of claims, affirmed by Sixth Circuit, resulting in hundreds of dismissals and favorable settlements.
- DaVita v. Baxter Healthcare: Led defense of Baxter in $400 million breach-of-contract bench trial regarding sale of dialysis equipment. Reduced Baxter’s potential damages exposure by 97% at summary judgment. Case settled favorably between closing argument and court ruling.
- Naturalock v. Baxter Healthcare: Lead trial counsel for Baxter in $300 million contract claim regarding development of catheter device. Case settled favorably one week before trial.
- Snizavich v. Rohm & Haas: Represented Rohm & Haas, a Dow subsidiary, in case alleging brain cancer caused by chemical exposure. Court excluded plaintiff’s chief causation expert and entered judgment for Rohm & Haas one day before trial.
False Claims Act
- U.S. ex rel. Hearrell v. Allergan: Lead counsel for Allergan in False Claims Act case alleging nationwide scheme to promote Botox off-label for use in children and payment of kickbacks. Court granted summary judgment for Allergan and dismissed the case in its entirety, weeks before trial.
- U.S. ex rel. Colquitt v. Abbott: Trial counsel for Abbott in False Claims Act case where whistleblower sought over $1 billion for allegedly false Medicare claims relating to off-label medical devices. Examined key witnesses during three-week jury trial that resulted in complete defense verdict. Fifth Circuit affirmed.
- Babjak v. AbbVie: Defended AbbVie against claims of False Claims Act retaliation brought by seven former employees following Office of Ethics and Compliance investigation. District court dismissed all claims.
Technology, Sports and Other Commercial Litigation
- Bowman v. IBM, Inc.: Wrote winning class certification opposition brief for IBM in putative class action alleging breach-of-contract, negligence and § 1983 claims relating to IBM’s contract to modernize Indiana’s Medicaid system. Class certification denied.
- Memorylink Corporation v. Motorola Inc.: Represented Motorola in contract, patent infringement and fraud litigation involving wireless video transmission technology. District court dismissed all claims and Federal Circuit affirmed.
- Scott v. General Motors: Represented GM in securities class action alleging misstatements and omissions in Initial Public Offering. Court dismissed all claims at pleading stage, and Second Circuit affirmed.
- Right Field Rooftops v. Chicago Cubs: Represented Chicago Cubs in breach of contract, defamation and antitrust action brought by rooftops surrounding Wrigley Field. Successfully defeated temporary restraining order to halt construction of outfield signs as part of stadium expansion. Court then dismissed all nine counts with prejudice and Seventh Circuit affirmed.
- G. William Hunter v. Derek Fisher: Represented NBA player Derek Fisher in litigation brought by Executive Director of NBA’s Players Association. Court dismissed all fourteen claims at pleading stage and awarded attorneys’ fees.
More
Recognition
Recognized by Chambers USA for Litigation: General Commercial – Up and Coming
Recommended as a “Next Generation Partner” in General Commercial Disputes by Legal 500
Recognized by Crain’s as a “Notable Litigator and Trial Attorney”
Profiled by Bloomberg Law, “They’ve Got Next: Healthcare and Life Sciences Fresh Face Diana Watral,” April 22, 2021
Named in Benchmark Litigation’s “40 & Under Hot List”
Recognized by Benchmark Litigation for products liability, commercial litigation and False Claims Act work
Profiled by Law360 as a “Rising Star” for trial work
Named “Litigator of the Week” by the American Lawyer
Credentials
Admissions & Qualifications
- Illinois
Education
- University of Chicago Law SchoolJ.D.with Highest Honors2010
Graduated first in class
Order of the Coif
Kirkland & Ellis Scholar
Executive Editor, The University of Chicago Law Review
- Georgetown UniversityB.A., Governmentmagna cum laude, with Honors, with Distinction2007